Let-7 isoforms have been shown to be increased in the cerebrospinal fluid of patients with Alzheimer’s disease [12,17], further suggesting that let-7/TLR7/TRAIL signaling could be involved in multiple neurodegenerative disorders and represent a useful therapeutic target. This evidence concerns the gene TLR7 and early-onset autosomal dominant Alzheimer disease.